PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Cefoperazone”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 307 records · Page 17Linked to original sources

[Use of cefoperazone in clinical practice].

The bacteriological and clinical efficacy and side effects of cefoperazone were studied in 45 patients with severe and moderate purulent inflammatory diseases. The study showed that its bacteriological and clinical efficacy was high in cases with peritonitis, cholecystitis, respiratory and urinary infections, as well as those of the eye and soft tissues. The general clinical efficacy amounted to 95.6 per cent. The number of the side effects was insignificant. This made it possible to recommend the use of cefoperazone in the therapy of many purulent inflammatory diseases, as well as in empirical therapy.

Adult↗

Detection of Campylobacter upsaliensis in diarrheic dogs and cats, using a selective medium with cefoperazone.

Using a newly formulated selective medium containing cefoperazone, we isolated 72 Campylobacter strains in fecal samples from 397 diarrheic dogs and cats. Of these, 39 were thermophilic catalase-negative Campylobacter species. We identified these Campylobacter strains by DNA:DNA hybridization, using digoxigenin-labeled total genomic DNA of 4 Campylobacter reference strains (C jejuni, C coli, C lari, and C upsaliensis) as a probe. The labeling was done with a commercially available kit. We could identify 66 of the 72 Campylobacter isolates to the species level with this method; identification with probes always agreed with conventional test results. Of the 66 identified strains, 33 were C upsaliensis and 33 were C jejuni. Six isolates could not be assigned to a known species with probes or conventional tests. On the basis of our findings, C upsaliensis is more resistant to cefoperazone than to cephalothin, thereby explaining the unexpected recovery of these campylobacters on cephalosporin-containing media.

Animals↗

[Comparison of efficacy between ceftriaxone and cefoperazone plus sulbactam in peri-operative treatment of acute suppurative cholangitis].

OBJECTIVE: To compare the efficacy of ceftriaxone and that of cefoperazone plus sulbactam (sulperazon) in controlling infection, in scavenging bacteria from bile, and in their costs when treating acute suppurative cholangitis with choledochostomy. METHODS: Patients were randomly assigned to two groups: the ceftriaxone group (R-group, n=95) and sulperazon group (S-group, n=95). Before choledochostomy, both groups received one intravenous dose of the corresponding antibiotics: and 2 g ceftriaxnoe for the R-group, 2 g sulperazon, containing 1 g cefoperazone and 1 g sulbactam, for the S-group. After the operation, the patients in the R-group received ceftriaxone 2 g i.v. q.d.; the patients in the S-group received sulperazon 2 g i.v. b.i.d.. In addition, all patients in both groups received metronidazole 0.5 g daily before and after the operation. The efficacy was evaluated by efficiency in controlling infection and the persisting days of symptoms due to infection, fever and leukocytosis; the persisting days was compared using the life table method to calculate the "cumulative probability of persistence of symptoms (CPPS)". The two groups were also compared in regards to their biliary bacterial clearance rates and the costs directly attributable to the antibiotics. RESULTS: The efficiency in controlling infection was 98.9% (94/95) in both groups. However, the CPPS of the R-group decreased more rapidly than that of the S-group, Log-Rankchi2=6.7901, P=0.0092. Biliary bacterial clearance rate on post-operative day 3 was 72.0% (36/50) for the R-group, 41.3% (19/46) for the S-group, P=0.0037. Cost directly attributable to the antibiotics were (1788.29 +/- 518.46) yuan (RMB) for the R-group, and (3768.74 +/- 820.55) yuan for the S-group, F=395.51, P=0.0000. CONCLUSION: Both ceftriaxone and sulperazon are effective in treating acute suppurative cholangitis when used before and after choledochostomy. Ceftriaxone is superior in expediting symptom relief and bacterial clearance from bile, and is more cost-effective.

Acute Disease↗

[Cefoperazone--Possibility of safer treatment for infections in patients with chronic renal failure].

Cefoperazone was used in the treatment of infections in 13 cases of chronic renal failure. In 8 cases recurrent urinary tract infections were diagnosed, septicaemia in 3 cases, pneumonia in 2. Cefoperazone 2-4 g daily was a very effective and well tolerated drug. Only one therapeutic failure was noted in a patient with mixed urinary tract infection (strains of Enterobacter cloacae and Klebsiella pneumoniae). No side effects developed, and in patients in the phase of moderate renal failure some decrease of serum creatinine was noted after the completion of treatment.

Adult↗

[In vitro activity of aztreonam, cefoperazone and ceftriaxone against gram-negative bacteria].

In this study, the in vitro activity of aztreonam was compared with that of cefoperazone and ceftriaxone against 1000 gram-negative bacilli. Among gram-negative bacteria, resistance to aztreonam, cefoperazone and ceftriaxone were noted 2.7%, 11.3%, 11.5% respectively. The results obtained in this study indicate that aztreonam is highly effective against gram-negative bacilli.

Aztreonam↗

[Cefoperazone in the treatment of infections in newborn infants].

The authors evaluated clinically cefoperazone (Cefobid-Pfizer)--an antibiotic of the III generation of cephalosporins--administering it in the form of monotherapy to 32 infected neonates and premature babies. A complete recovery was achieved im 25 neonates, i.e. 78.1%, out of which 76.5% were generalized infections. The result of therapy was doubtful in the remaining 7 babies (21.9%). The drug was changed or the second antibiotic added. No decidedly unfavourable results (deaths) or adverse reactions necessitating withdrawal of the drug were observed. The authors compare this favourable results with the mortality rate of neonates prior to the introduction of the II and III generation cephalosporins. It was about 14%, then. Therefore, both +antibiotic monotherapy and cefoperazone enabling its use are worth wide popularization in neonates and small babies.

Bacterial Infections↗

[Effect of cefoperazone on the activity of selected parameters of cellular immunity in mice with experimental viral-bacterial infection].

We applied mixed, viral-bacterial infections of mice (with influenza virus to the respiratory tract and Staphylococcus aureus) intereperitoneally. We used Sodium Cefoperazone subcutaneously in the dose of 30 mg/kg body weight 24, 48 and 72 hours after the infection. We evaluated phagocytic activity of the granulocytes isolated from animals and bactericidal activity of these cells expressed as their chemiluminescent activity. We studied it on the 3rd, 6th, 9th, and the 14th day after the infection. Phagocytic activity of cells taken from infected mice and treated with the preparation expressed as phagocytic index was the following: 0.38, 0.19; 0.88; 0.99 respectively. In the comparative studies, concerning the effect of preincubation of cells with antibiotic (at the concentration produced in blood serum by therapeutic doses) we found the increase in chemiluminescent process by 57% on the average. Analyzing the preliminary data form the experimental studies on the influence of Cefoperazone on mixed, viral-bacterial infections in mice we found the positive effect of the antibiotic evaluated in some immunological test. Intracellular killing of bacteria is stimulated. Preincubation of granulocytes with the antibiotic gives higher chemiluminescent activity of cells. However, chemotactic and phagocytic activity of cells are not changed.

Animals↗

Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation.

Seventy hospitalized patients with upper urinary tract infections were treated with cefoperazone (2 gm) and sulbactam (1 gm) every 12 hours for three or more days. All but six patients also received vitamin K. Forty of the 70 patients (57%) were cured of infection at one week after treatment, 13 relapsed, 11 had reinfections, and six were lost to follow-up. There were no treatment failures. Escherichia coli was the predominant pathogen (62% of isolates). Overall there was 15% resistance to cefoperazone and all resistant isolates were susceptible to the combination of agents. Synergy was demonstrated in 26% of isolates. One uroseptic patient who had an organism resistant to both study agents, but susceptible to the combination, was cured. Two of six patients who did not receive vitamin K demonstrated abnormal coagulation patterns and one had an associated major bleeding complication. Although 12 of 64 (19%) patients who received vitamin K had at least one coagulation abnormality, there were no significant bleeding complications in this group.

Adolescent↗

Worldwide study of cefoperazone susceptibility.

In vitro susceptibility to cefoperazone of more than one million clinical aerobic bacterial isolates was evaluated in 369 hospitals in Japan, the United States, Canada, France, Austria, and Hungary. Standard versions of the disk diffusion method were used according to interpretive criteria approved in the respective countries, and comparisons were made among the countries and among various body sites. Susceptibility of organisms varied little within most species among the countries. Minor differences in methodology and in interpretive criteria may explain some of the variations observed among countries and hospitals. The susceptibility of key pathogens to cefoperazone among countries ranged from 91% to 98% for Escherichia coli, 73% to 91% for Pseudomonas aeruginosa, 90% to 95% for Klebsiella pneumoniae, 73% to 92% for Enterobacter cloacae, 74% to 92% for Staphylococcus aureus, and 91% to 97% for Proteus mirabilis. Susceptibility of isolates from the urinary tract did not vary markedly from that in other body sites.

Cefoperazone↗

Disposition and excretion of cefoperazone in rabbits.

The pharmacokinetics of cefoperazone were studied after i.v. administration of a single 30 mg/kg dose in a total of 40 New Zealand rabbits. Determination of the plasma levels of the drug revealed a slow elimination half-life of 0.48 h. The disappearance half-life of cefoperazone in interstitial tissue fluid shows a mean value of 1.9 h, being statistically higher than the value found for the half-life of the slow phase of elimination from the systemic circulation. 12 h after i.v. administration, 32.1% of the drug was seen to be excreted by the kidney and a further 15.2% in bile. The urinary excretion constant had a mean value of 0.29 h-1, whereas that of biliary excretion was 0.12 h-1.

Animals↗

The effect of control on the pattern of utilization of cefotaxime, moxalactam and cefoperazone in a teaching hospital.

In a 710-bed teaching hospital, the infectious disease section and pharmacy service initiated a joint programme to control and monitor the use of third-generation cephalosporins (TGC): cefotaxime, moxalactam and cefoperazone. The policy requires that an infectious disease physician approve the use of a TGC prior to its administration. This retrospective study sought to assess the pattern of utilization of these agents. From January to December 1983, 109 patient courses of cefotaxime (CT), moxalactam (MX), and cefoperazone (CP) were tabulated. Records from 92 patient courses were available for review (84.4%). The preliminary data show that 46.7% of TGC were used empirically to treat suspected infections without culture and sensitivity data, while 50.0% were used to treat various infections (central nervous system, pulmonary, wound, abdominal, biliary, urinary and blood) after culture and sensitivities were known. Only 3.3% of the TGC were used for surgical prophylaxis. In the empirical treatment group, the leading indications for use of TGC were central nervous system (CT = 40.0%, MX = 48.0%) and biliary (CP = 23.1%) infections. In the treatment group with culture and sensitivity data, the primary uses of TGC were for the treatment of Gram-negative pulmonary (MX = 28.0%, CP = 19.2%) and wound (CP = 15.4%) infections. This study shows that physician and pharmacy control does not eliminate empirical treatment with TGC; but it does narrow their use to situations in which their properties are best exploited.

Bacterial Infections↗

Comparative in vitro and in vivo activity of cefminox (MT-141), cefotaxime and cefoperazone against gram-negative bacteria.

Against 17 Gram-negative bacteria, excluding Proteus species, the difference between cefminox and cefotaxime was significant in terms of MIC distribution, in favour of cefotaxime, but was not significant in terms of ED50 distribution. Against 22 Proteus species, the difference between cefminox and cefotaxime was not significant in terms of MIC distribution, but was significant for ED50 distribution, in favour of cefminox. The difference between cefminox and cefoperazone was not significant for either MIC or ED50 distribution against 17 Gram-negative bacteria, but was significant against 22 Proteus species, in favour of cefminox. The distribution of rank of the ED50/MIC ratios for cefminox was significantly lower than those for cefotaxime and cefoperazone, indicating that cefminox showed lower ED50 values than expected from the MIC values.

Animals↗

[Multicenter study of cefoperazone in Austria].

109 patients entered a multicentre study for treatment with Cefoperazone of respiratory, urogenital, and hepato-biliary tract infections, as well as peritonitis. The purpose of the study was to determine the efficacy, tolerance as well as the therapeutic advantages of a new agent of the group of betalactam-antibiotics which is excreted by the liver with the bile and--to a far lesser extent--by the kidneys. The mean duration of therapy was 7.2 days. The mean dosage was 2 g twice a day. Efficacy and tolerance of Cefoperazone were excellent.

Adolescent↗

A pharmacokinetic study of cefoperazone.

A pharmacokinetic study of cefoperazone on rats showed long half-life in serum and kidney. The most remarkable finding was that the drug was not detected in the fraction of mitochondria and lysosomes in all the experiment animals. The finding suggests the low nephrotoxic characteristics of cefoperazone.

Animals↗

[Cefoperazone: microbiological, kinetic and clinical studies].

In vitro cefoperazone proved more active against the tested gram-negative bacteria than either piperacillin or mezlocillin. When administered in 1 g venous bolus the antibiotic achieved high plasmatic concentrations that were still adequate after 8 hours. 33.2% was excreted by the kidneys and a considerable amount by the biliary way. Cefoperazone produced a clinical cure in 35/36 patients (97.22%). A disulfiram-like effect was noted in 18.18%.

Bacterial Infections↗

Effectiveness of cefoperazone in treating cutaneous infections.

Twenty-eight patients with severe cutaneous infections received cefoperazone, 2 grams intramuscularly twice a day for seven days. A wide range of gram-positive and gram-negative pathogens were isolated from admission cultures. All patients showed rapid clinical improvement. Two patients did not complete the full course of therapy because of intervening medical problems unrelated to the antibiotic. No significant side effects were noted. Relapses or reinfections occurred in two patients. In conclusions, cefoperazone is a safe and effective antibiotic for use in skin infections requiring parenteral therapy.

Alcohol Deterrents↗

Treatment of lower respiratory tract infections with cefoperazone.

Fifteen patients with documented bacterial lower respiratory tract infections were treated with cefoperazone (2 gm every 12 hours, administered parenterally) as the single antibiotic therapy. Pulmonary infections included pneumonia (10), anaerobic lung abscess (2), bronchitis (2), and exacerbation of bronchiectasis (1); most of the patients had concomitant illnesses that compromised their host-immune status. Bacteria recovered from respiratory tract cultures included aerobic gram-negative bacilli (17), anaerobes (6), and aerobic gram-positive cocci (3). After therapy, lasting 5 to 28 days, nine patients had complete resolution of their infection, and the remaining six patients had significant clinical improvement. Diarrhea was the adverse reaction most commonly noted; others included an unusual reaction resembling serum sickness, and, in one patient treated for 24 days, hypotension and a subsequent decrease in renal function. Drug-related abnormalities in blood and serum values were few and mild. Cefoperazone was found to be effective in the treatment of lower respiratory tract infections.

Adult↗